

Haematologica  
HAEMATOL/2018/202283  
Version 3

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia

Michael D. Tarantino, James B. Bussel, Victor S. Blanchette, Donald Beam, John Roy, Jenny Despotovic, Ashok Raj, Nancy Carpenter, Bhakti Mehta, and Melissa Eisen

Disclosures: Michael D. Tarantino has received research funding from Grifols and Novo Nordisk; is on advisory boards for Baxalta, Biogen, Grifols, Novo Nordisk, and Pfizer; is a speaker for Biogen and Grifols; reviews grants for Pfizer, and has grants from HRSA and CDC. James B. Bussel has received research funding from Amgen Inc., Novartis, Prophylix, Protalex, and Rigel; is on advisory boards for Amgen Inc., Momenta, Novartis, Prophylix, Protalex, and Rigel; has received honoraria from UpToDate. Victor S. Blanchette has received research funding from Biogen/Bioverativ and Shire; has received honoraria for participation in advisory boards and speaker fees from Bayer Healthcare, Novo Nordisk, Pfizer, and Shire; is a member of the Data Safety Monitoring Boards for Octapharma and Shire. Donald Beam, John Roy, and Jenny Despotovic have no disclosures. Ashok Raj has received speaking fees from Novartis; served on advisory boards for Bayer, Biogen, Octapharma, Pfizer, and Shire. Nancy Carpenter, Bhakti Mehta, and Melissa Eisen are employees of and stockholders in Amgen Inc.

Contributions: All authors were involved in the acquisition of data, either through study sites or as part of the study teams, as well as analysis and interpretation of the data. Further, all authors contributed to the writing of the report through critical review, comments, and approval of early drafts of the report, and all authors approved the final draft for publication. Susanna Mac, a medical writer from Amgen Inc., assisted the authors with drafting the manuscript and revised the manuscript based on extensive guidance from the authors.